MediciNova (NASDAQ:MNOV) Issues Quarterly Earnings Results

Posted by Brian Himes on Aug 15th, 2026

MediciNova (NASDAQ:MNOV – Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01, FiscalAI reports. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.07 million. MediciNova had a negative net margin of 1,168.70% and a negative return on equity of 25.81%.

MediciNova Price Performance

Shares of NASDAQ:MNOV remained flat at $1.31 during trading on Friday. 45,061 shares of the stock were exchanged, compared to its average volume of 32,636. MediciNova has a 12 month low of $1.17 and a 12 month high of $1.96. The stock has a market capitalization of $64.48 million, a price-to-earnings ratio of -6.24 and a beta of 0.63. The firm’s 50 day moving average is $1.34 and its two-hundred day moving average is $1.41.

Analyst Ratings Changes

MNOV has been the subject of several analyst reports. Weiss Ratings lowered shares of MediciNova from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of MediciNova in a report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, MediciNova has an average rating of “Moderate Buy” and an average price target of $8.33.

Check Out Our Latest Research Report on MediciNova

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. StoneX Group Inc. bought a new position in MediciNova in the 4th quarter worth $25,000. Goldman Sachs Group Inc. bought a new position in shares of MediciNova in the fourth quarter worth about $35,000. Citadel Advisors LLC acquired a new position in shares of MediciNova during the 3rd quarter worth about $92,000. Jane Street Group LLC bought a new stake in MediciNova during the 4th quarter valued at approximately $214,000. Finally, State Street Corp grew its holdings in MediciNova by 10.9% in the 4th quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 19,100 shares during the last quarter. 9.90% of the stock is currently owned by institutional investors and hedge funds.

MediciNova Company Profile

(Get Free Report)

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.